BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lacruz-Guzmán D, Torres-Moreno D, Pedrero F, Romero-Cara P, García-Tercero I, Trujillo-Santos J, Conesa-Zamora P. Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn’s disease and ulcerative colitis. Eur J Clin Pharmacol. 2013;69:431-438. [PMID: 22960943 DOI: 10.1007/s00228-012-1389-0] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Muro M, Mrowiec A. Interleukin (IL)-1 Gene Cluster in Inflammatory Bowel Disease: Is IL-1RA Implicated in the Disease Onset and Outcome? Dig Dis Sci 2015;60:1126-8. [DOI: 10.1007/s10620-015-3571-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
2 Muro M, López-Hernández R, Mrowiec A. Immunogenetic biomarkers in inflammatory bowel diseases: Role of the IBD3 region. World J Gastroenterol 2014; 20(41): 15037-15048 [PMID: 25386052 DOI: 10.3748/wjg.v20.i41.15037] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
3 van den Bosch BJ, Coenen MJ. Pharmacogenetics of inflammatory bowel disease. Pharmacogenomics 2021;22:55-66. [PMID: 33305616 DOI: 10.2217/pgs-2020-0095] [Reference Citation Analysis]
4 Afrin MR, Arumugam S, Rahman MA, Karuppagounder V, Sreedhar R, Harima M, Suzuki H, Nakamura T, Miyashita S, Suzuki K, Ueno K, Watanabe K. Le Carbone, a charcoal supplement, modulates DSS-induced acute colitis in mice through activation of AMPKα and downregulation of STAT3 and caspase 3 dependent apoptotic pathways. International Immunopharmacology 2017;43:70-8. [DOI: 10.1016/j.intimp.2016.10.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
5 Qian B, Wang C, Zeng Z, Ren Y, Li D, Song JL. Ameliorative Effect of Sinapic Acid on Dextran Sodium Sulfate- (DSS-) Induced Ulcerative Colitis in Kunming (KM) Mice. Oxid Med Cell Longev 2020;2020:8393504. [PMID: 33312339 DOI: 10.1155/2020/8393504] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Ye C, Zhu S, Yuan J. Characterization of Two TNF-Related Subtypes Predicting Infliximab Therapy Responses in Crohn’s Disease. Front Immunol 2022;13:871312. [DOI: 10.3389/fimmu.2022.871312] [Reference Citation Analysis]
7 Chatterjee A, Gogolak P, Blottière HM, Rajnavölgyi É. The impact of ATRA on shaping human myeloid cell responses to epithelial cell-derived stimuli and on T-lymphocyte polarization. Mediators Inflamm 2015;2015:579830. [PMID: 25944986 DOI: 10.1155/2015/579830] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
8 Katsanos KH, Papadakis KA. Pharmacogenetics of inflammatory bowel disease. Pharmacogenomics 2014;15:2049-62. [PMID: 25521361 DOI: 10.2217/pgs.14.154] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
9 Lima BR, Nussenblatt RB, Sen HN. Pharmacogenetics of drugs used in the treatment of ocular inflammatory diseases. Expert Opin Drug Metab Toxicol 2013;9:875-82. [PMID: 23521173 DOI: 10.1517/17425255.2013.783818] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
10 McLean MH, Neurath MF, Durum SK. Targeting interleukins for the treatment of inflammatory bowel disease-what lies beyond anti-TNF therapy? Inflamm Bowel Dis. 2014;20:389-397. [PMID: 24356385 DOI: 10.1097/01.mib.0000437616.37000.41] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 3.9] [Reference Citation Analysis]
11 Sarani H, Mollashahi B, Taheri M, Bahari G, Hashemi SM, Hashemi M, Ghavami S. Association between the IL-1A, IL-1B and IL-1R polymorphisms and lymphoma. Nucleosides Nucleotides Nucleic Acids 2021;40:707-19. [PMID: 34159887 DOI: 10.1080/15257770.2021.1929317] [Reference Citation Analysis]
12 Stolarski AE, Kim J, Zhang Q, Remick DG. Cytokine Drizzle-The Rationale for Abandoning "Cytokine Storm". Shock 2021;56:667-72. [PMID: 34652339 DOI: 10.1097/SHK.0000000000001769] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zhang J, Shi G. Lymphocyte infiltration and key differentially expressed genes in the ulcerative colitis. Medicine (Baltimore) 2020;99:e21997. [PMID: 32871953 DOI: 10.1097/MD.0000000000021997] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Meddens CA, van der List ACJ, Nieuwenhuis EES, Mokry M. Non-coding DNA in IBD: from sequence variation in DNA regulatory elements to novel therapeutic potential. Gut 2019;68:928-41. [DOI: 10.1136/gutjnl-2018-317516] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
15 Oliveira A, Dinis-Oliveira RJ, Nogueira A, Gonçalves F, Silva P, Vieira C, Silvestre R, Carvalho F, Medeiros R. Interleukin-1β genotype and circulating levels in cancer patients: metastatic status and pain perception. Clin Biochem 2014;47:1209-13. [PMID: 24747159 DOI: 10.1016/j.clinbiochem.2014.04.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
16 Korolkova OY, Myers JN, Pellom ST, Wang L, M'Koma AE. Characterization of Serum Cytokine Profile in Predominantly Colonic Inflammatory Bowel Disease to Delineate Ulcerative and Crohn's Colitides. Clin Med Insights Gastroenterol. 2015;8:29-44. [PMID: 26078592 DOI: 10.4137/cgast.s20612] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
17 Somogyi AA, Sia AT, Tan EC, Coller JK, Hutchinson MR, Barratt DT. Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain. Pain 2016;157:2458-66. [PMID: 27649267 DOI: 10.1097/j.pain.0000000000000661] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
18 Gisbert JP, Chaparro M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 2020;14:694-709. [DOI: 10.1093/ecco-jcc/jjz195] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 12.7] [Reference Citation Analysis]
19 Crommelin H, Vorselaars A, van der Vis J, Deneer V, van Moorsel CHM. Pharmacogenetics of antitumor necrosis factor therapy in severe sarcoidosis. Curr Opin Pulm Med 2020;26:267-76. [PMID: 32205584 DOI: 10.1097/MCP.0000000000000681] [Reference Citation Analysis]
20 McKinney C, Stamp LK, Dalbeth N, Topless RK, Day RO, Kannangara DR, Williams KM, Janssen M, Jansen TL, Joosten LA, Radstake TR, Riches PL, Tausche AK, Lioté F, So A, Merriman TR. Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout. Arthritis Res Ther 2015;17:288. [PMID: 26462562 DOI: 10.1186/s13075-015-0802-3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
21 Thomas D, Gazouli M, Karantanos T, Rigoglou S, Karamanolis G, Bramis K, Zografos G, Theodoropoulos GE. Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn’s disease. World J Gastroenterol 2014; 20(13): 3609-3614 [PMID: 24707144 DOI: 10.3748/wjg.v20.i13.3609] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
22 Romero-Cara P, Torres-Moreno D, Pedregosa J, Vílchez JA, García-Simón MS, Ruiz-Merino G, Morán-Sanchez S, Conesa-Zamora P. A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF. Int J Med Sci 2018;15:10-5. [PMID: 29333082 DOI: 10.7150/ijms.22812] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
23 Atreya R, Neurath MF, Siegmund B. Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF? Front Med (Lausanne) 2020;7:517. [PMID: 32984386 DOI: 10.3389/fmed.2020.00517] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
24 Gole B, Potočnik U. Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn's Disease-A Systematic Review and Gene Ontology Analysis. Cells 2019;8:E515. [PMID: 31141991 DOI: 10.3390/cells8060515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
25 Nishikawa R, Nagai H, Bito T, Ikeda T, Horikawa T, Adachi A, Matsubara T, Nishigori C. Genetic prediction of the effectiveness of biologics for psoriasis treatment. J Dermatol 2016;43:1273-7. [DOI: 10.1111/1346-8138.13412] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
26 Park JH, Jeong DY, Peyrin-Biroulet L, Eisenhut M, Shin JI. Insight into the role of TSLP in inflammatory bowel diseases. Autoimmun Rev 2017;16:55-63. [PMID: 27697608 DOI: 10.1016/j.autrev.2016.09.014] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
27 Balaha M, Kandeel S, Elwan W. Garlic oil inhibits dextran sodium sulfate-induced ulcerative colitis in rats. Life Sci 2016;146:40-51. [PMID: 26780265 DOI: 10.1016/j.lfs.2016.01.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
28 Zhang H, Zeng Z, Mukherjee A, Shen B. Molecular diagnosis and classification of inflammatory bowel disease. Expert Rev Mol Diagn. 2018;18:867-886. [PMID: 30152711 DOI: 10.1080/14737159.2018.1516549] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
29 Linares-pineda TM, Cañadas-garre M, Sánchez-pozo A, Calleja-hernández MÁ. Pharmacogenetic biomarkers of response in Crohn’s disease. Pharmacogenomics J 2018;18:1-13. [DOI: 10.1038/tpj.2017.27] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
30 Bank S, Julsgaard M, Abed OK, Burisch J, Broder Brodersen J, Pedersen NK, Gouliaev A, Ajan R, Nytoft Rasmussen D, Honore Grauslund C, Roug S, Galsgaard J, Sprogøe Høyer Finsen D, Lindby K, Sørensen J, Larsen L, Rohr Andersen M, Brandslund I, Thomassen M, Green A, Bo Bojesen A, Bek Sørensen S, Vogel U, Andersen V; Danish IBD Genetics Working Group. Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease. Aliment Pharmacol Ther 2019;49:890-903. [PMID: 30811631 DOI: 10.1111/apt.15187] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
31 Harati-Sadegh M, Mohammadoo-Khorasani M, Sargazi S, Saravani R, Shahraki S, Eskandari E. Quantitative Assessment of the Effects of IL-1ß -511 C>T Variant on Breast Cancer Risk: An Updated Meta-Analysis of 3331 Cases and 3609 Controls. Lab Med 2021;52:36-46. [PMID: 32754752 DOI: 10.1093/labmed/lmaa055] [Reference Citation Analysis]
32 Walczak M, Lykowska-Szuber L, Plucinska M, Stawczyk-Eder K, Zakerska-Banaszak O, Eder P, Krela-Kazmierczak I, Michalak M, Zywicki M, Karlowski WM, Szalata M, Dobrowolska A, Slomski R, Skrzypczak-Zielinska M. Is Polymorphism in the Apoptosis and Inflammatory Pathway Genes Associated With a Primary Response to Anti-TNF Therapy in Crohn's Disease Patients? Front Pharmacol 2020;11:1207. [PMID: 32922288 DOI: 10.3389/fphar.2020.01207] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Salvador-Martín S, Melgarejo-Ortuño A, López-Fernández LA. Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease. Pharmaceutics 2021;13:1786. [PMID: 34834201 DOI: 10.3390/pharmaceutics13111786] [Reference Citation Analysis]
34 Chen P, Zhou G, Lin J, Li L, Zeng Z, Chen M, Zhang S. Serum Biomarkers for Inflammatory Bowel Disease. Front Med (Lausanne). 2020;7:123. [PMID: 32391365 DOI: 10.3389/fmed.2020.00123] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
35 Lin K, Mahadevan U. Pharmacokinetics of Biologics and the Role of Therapeutic Monitoring. Gastroenterology Clinics of North America 2014;43:565-79. [DOI: 10.1016/j.gtc.2014.05.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
36 Relizani K, Le Corf K, Kropp C, Martin-rosique R, Kissi D, Déjean G, Bruno L, Martinez C, Rawadi G, Elustondo F, Mazier W, Claus SP. Selection of a novel strain of Christensenella minuta as a future biotherapy for Crohn’s disease. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-10015-3] [Reference Citation Analysis]
37 Tavakolpour S, Darvishi M, Ghasemiadl M. Pharmacogenetics: A strategy for personalized medicine for autoimmune diseases. Clin Genet 2018;93:481-97. [PMID: 29194620 DOI: 10.1111/cge.13186] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
38 Sugimoto K, Ikeya K, Bamba S, Andoh A, Yamasaki H, Mitsuyama K, Nasuno M, Tanaka H, Matsuura A, Kato M, Ishida N, Tamura S, Takano R, Tani S, Osawa S, Nishihira J, Hanai H. Highly bioavailable curcumin derivative ameliorates Crohn's disease symptoms: A randomized, double-blind, multicenter study. J Crohns Colitis 2020:jjaa097. [PMID: 32412598 DOI: 10.1093/ecco-jcc/jjaa097] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
39 Kim JM, Kim DH, Park HJ, Ma HW, Park IS, Son M, Ro SY, Hong S, Han HK, Lim SJ, Kim SW, Cheon JH. Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model. J Nanobiotechnology 2020;18:133. [PMID: 32933548 DOI: 10.1186/s12951-020-00693-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
40 Bank S, Andersen PS, Burisch J, Pedersen N, Roug S, Galsgaard J, Turino SY, Brodersen JB, Rashid S, Rasmussen BK. Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. Pharmacogenomics J. 2014;14:526-534. [PMID: 24776844 DOI: 10.1038/tpj.2014.19] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 9.5] [Reference Citation Analysis]
41 Ren TH, Lv MM, An XM, Leung WK, Seto WK. Activation of adenosine A3 receptor inhibits inflammatory cytokine production in colonic mucosa of patients with ulcerative colitis by down-regulating the nuclear factor-kappa B signaling. J Dig Dis 2020;21:38-45. [PMID: 31714673 DOI: 10.1111/1751-2980.12831] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
42 Lauro R, Mannino F, Irrera N, Squadrito F, Altavilla D, Squadrito G, Pallio G, Bitto A. Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review. Biomedicines 2021;9:1748. [PMID: 34944563 DOI: 10.3390/biomedicines9121748] [Reference Citation Analysis]
43 Prieto-Pérez R, Almoguera B, Cabaleiro T, Hakonarson H, Abad-Santos F. Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease. Int J Mol Sci 2016;17:225. [PMID: 26861312 DOI: 10.3390/ijms17020225] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
44 Stevens TW, Matheeuwsen M, Lönnkvist MH, Parker CE, Wildenberg ME, Gecse KB, D’haens GR. Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy. Aliment Pharmacol Ther 2018;48:1213-31. [DOI: 10.1111/apt.15033] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
45 Kim KU, Kim J, Kim WH, Min H, Choi CH. Treatments of inflammatory bowel disease toward personalized medicine. Arch Pharm Res 2021;44:293-309. [PMID: 33763844 DOI: 10.1007/s12272-021-01318-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Yamamoto-furusho JK, Fonseca-camarillo G. Genetic Markers Associated with Clinical Outcomes in Patients with Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2015;21:2683-95. [DOI: 10.1097/mib.0000000000000500] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
47 Rufini S, Ciccacci C, Novelli G, Borgiani P. Pharmacogenetics of inflammatory bowel disease: a focus on Crohn's disease. Pharmacogenomics 2017;18:1095-114. [PMID: 28686143 DOI: 10.2217/pgs-2017-0068] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
48 Loft ND, Skov L, Iversen L, Gniadecki R, Dam TN, Brandslund I, Hoffmann HJ, Andersen MR, Dessau RB, Bergmann AC, Andersen NM, Andersen PS, Bank S, Vogel U, Andersen V. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis. Pharmacogenomics J 2018;18:494-500. [DOI: 10.1038/tpj.2017.31] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
49 De Santis S, Kunde D, Galleggiante V, Liso M, Scandiffio L, Serino G, Pinto A, Campiglia P, Sorrentino R, Cavalcanti E, Santino A, Caruso ML, Eri R, Chieppa M. TNFα deficiency results in increased IL-1β in an early onset of spontaneous murine colitis. Cell Death Dis 2017;8:e2993-e2993. [DOI: 10.1038/cddis.2017.397] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
50 Zaaber I, Mestiri S, Hammedi H, Marmouch H, Mahjoub S, Tensaout BB, Said K. Association of Interleukin-1B and Interleukin-4 Gene Variants with Autoimmune Thyroid Diseases in Tunisian Population. Immunol Invest 2016;45:284-97. [PMID: 27100882 DOI: 10.3109/08820139.2016.1153650] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
51 Di Paolo A, Luci G. Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond. Front Pharmacol 2020;11:610806. [PMID: 33628180 DOI: 10.3389/fphar.2020.610806] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
52 Korver SK, Gibson RJ, Bowen JM, Coller JK. Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 2019;83:217-36. [PMID: 30474704 DOI: 10.1007/s00280-018-3729-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
53 Daryani NE, Sadr M, Moossavi S, Shahkarami S, Soltani S, Farhadi E, Rezaei N. Significance of IL-1RA Polymorphism in Iranian Patients with Inflammatory Bowel Disease. Dig Dis Sci 2015;60:1389-95. [PMID: 25466956 DOI: 10.1007/s10620-014-3457-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
54 Mahajna H, Ben-Horin S. Novel bio-genetic predictors of response to biologic treatment in inflammatory bowel diseases. Curr Opin Pharmacol 2020;55:132-40. [PMID: 33249396 DOI: 10.1016/j.coph.2020.10.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Schneider A, Hossain I, VanderMolen J, Nicol K. Comparison of remicade to curcumin for the treatment of Crohn's disease: A systematic review. Complement Ther Med 2017;33:32-8. [PMID: 28735823 DOI: 10.1016/j.ctim.2017.06.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
56 Wang J, Shi Y, Wang G, Dong S, Yang D, Zuo X. The association between interleukin-1 polymorphisms and their protein expression in Chinese Han patients with breast cancer. Mol Genet Genomic Med 2019;7:e804. [PMID: 31297985 DOI: 10.1002/mgg3.804] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
57 Harati-Sadegh M, Sargazi S, Khorasani M, Ansari-Moghaddam A, Mirinejad S, Sheervalilou R, Saravani R. IL1A and IL1B gene polymorphisms and keratoconus susceptibility: evidence from an updated meta-analysis. Ophthalmic Genet 2021;:1-11. [PMID: 33978542 DOI: 10.1080/13816810.2021.1925926] [Reference Citation Analysis]